Panaxia
Tel Aviv, Israel· Est.
Israeli pharma‑grade cannabis developer delivering standardized oral and inhalation products for global markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
AI Company Overview
Israeli pharma‑grade cannabis developer delivering standardized oral and inhalation products for global markets.
Pain ManagementNeurologyOncology Supportive Care
Technology Platform
GMP‑certified extraction and formulation platform delivering standardized cannabinoid products in sublingual, inhalation and rectal dosage forms with validated analytical methods.
Opportunities
Expansion into EU markets via EU‑GMP certified production, and growing demand for non‑smoking, precisely dosed cannabinoid medicines.
Risk Factors
Regulatory changes, reimbursement hurdles, and competition from larger pharma‑cannabis players could limit market uptake.
Competitive Landscape
Competes with GW Pharmaceuticals, Tilray, and other GMP cannabis producers; differentiates through sublingual tablets, inhalation extracts, and a strong focus on pharma‑grade standardization.